chronic spontaneous urticaria

sale for sale sell

Biotech

Third Harmonic’s song to end as biotech looks to liquidate

Third Harmonic has abandoned plans to take its urticaria drug into phase 2, instead preparing to sell the asset while liquidating the business.

James Waldron Apr 14, 2025 9:01am

Honeybees on honeycomb in hive

Novartis hands over $55M to license preclinical hives prospect

Mar 3, 2025 5:05pm

Businessman puts his box of his belongs on the desk and holds a white letter

Third Harmonic halves headcount to take urticaria drug to ph. 2

Feb 11, 2025 7:58am

Illustration of the concept of layoff and downsizing of staff

Allakos axes program, lays off 75% of staff after phase 1 flop

Jan 27, 2025 8:46am

pause hold stop delay

Incyte's $750M buyout rocked by pause on key trial, asset cull

Nov 19, 2024 4:12am

Arrow increasing

Jasper dials up dose after hives responses come and go quickly

Oct 14, 2024 9:43am